PHASE Scientific Launches RNA Extraction Kit for COVID-19 Test
By LabMedica International staff writers Posted on 10 Apr 2020 |
Image: PHASIFY VIRAL RNA Extraction Kit (Photo courtesy of PHASE Scientific)
PHASE Scientific (Hong Kong) has commercially launched the PHASIFY VIRAL RNA Extraction Kit as part of its global effort to help detect and control the COVID-19 disease. PHASIFY VIRAL purifies and concentrates viral RNA in patient viral transport media samples. This novel technology outperforms conventional solid phase extraction methods in RNA yield and concentration.
PHASE Scientific is a biotech company which builds tools that empower people by giving them better information about their health. The PHASIFY VIRAL kit, which incorporates the PHASIFY proprietary liquid phase extraction technology, produces greater viral RNA yields. This is enabled by an increased sample input volume up to 1 mL per extraction, and enhanced final viral RNA concentration with flexible elution volume down to 10 µL. The kit’s easy-to-use design requires no additional specialized equipment, such as magnetic racks and vacuum pumps, for operation.
PHASIFY concentrates target molecules by 10-100x, making them easier to detect. PHASIFY can make any diagnostic test more affordable, faster, easier, and more accurate. As proven by validation data, the PHASIFY VIRAL RNA extraction kit enables a 3-6 cycle threshold reduction compared to solid phase extraction. The applications of the PHASIFY VIRAL RNA Extraction Kit can be expanded to cover a wide scope of RNA-type virus extractions to help research institutes, hospitals, and diagnostic labs to improve diagnostic performance.
“We believe the PHASIFY VIRAL kit will be a new breakthrough approach for the fight against the COVID-19 disease. Our products can help increase detection sensitivity, decrease false negative results, enable earlier detection and increase confidence in diagnostic test results,” said Ricky Chiu, Ph.D., Founder and CEO of PHASE Scientific.
Related Links:
PHASE Scientific
PHASE Scientific is a biotech company which builds tools that empower people by giving them better information about their health. The PHASIFY VIRAL kit, which incorporates the PHASIFY proprietary liquid phase extraction technology, produces greater viral RNA yields. This is enabled by an increased sample input volume up to 1 mL per extraction, and enhanced final viral RNA concentration with flexible elution volume down to 10 µL. The kit’s easy-to-use design requires no additional specialized equipment, such as magnetic racks and vacuum pumps, for operation.
PHASIFY concentrates target molecules by 10-100x, making them easier to detect. PHASIFY can make any diagnostic test more affordable, faster, easier, and more accurate. As proven by validation data, the PHASIFY VIRAL RNA extraction kit enables a 3-6 cycle threshold reduction compared to solid phase extraction. The applications of the PHASIFY VIRAL RNA Extraction Kit can be expanded to cover a wide scope of RNA-type virus extractions to help research institutes, hospitals, and diagnostic labs to improve diagnostic performance.
“We believe the PHASIFY VIRAL kit will be a new breakthrough approach for the fight against the COVID-19 disease. Our products can help increase detection sensitivity, decrease false negative results, enable earlier detection and increase confidence in diagnostic test results,” said Ricky Chiu, Ph.D., Founder and CEO of PHASE Scientific.
Related Links:
PHASE Scientific
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants